PharmacyCodes



LEVOMYSOL en es it fr

LEVOMYSOL Brand names, LEVOMYSOL Analogs

LEVOMYSOL Brand Names Mixture

  • No information avaliable

LEVOMYSOL Chemical_Formula

C16H20FN3O4

LEVOMYSOL RX_link

http://www.rxlist.com/cgi/generic3/linezolid.htm

LEVOMYSOL fda sheet

LEVOMYSOL FDA

LEVOMYSOL msds (material safety sheet)

LEVOMYSOL MSDS

LEVOMYSOL Synthesis Reference

No information avaliable

LEVOMYSOL Molecular Weight

337.346 g/mol

LEVOMYSOL Melting Point

No information avaliable

LEVOMYSOL H2O Solubility

3 mg/mL

LEVOMYSOL State

Solid

LEVOMYSOL LogP

0.232

LEVOMYSOL Dosage Forms

Solution; Tablets

LEVOMYSOL Indication

For the treatment of bacterial infections caused by susceptible strains of vancomycin resistant Enterococcus faecium, Staphylococcal aureus (methicillin resistant and susceptible strains), Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus agalactiae.

LEVOMYSOL Pharmacology

Linezolid is a synthetic antibacterial agent of a new class of antibiotics, the oxazolidinones, which has clinical utility in the treatment of infections caused by aerobic Gram-positive bacteria. The in vitro spectrum of activity of linezolid also includes certain Gram-negative bacteria and anaerobic bacteria. Susceptible organisms include methicillin- and vancomycin-resistant staphylococci, vancomycin-resistant enterococci, penicillin-resistant pneumococci and anaerobes. Oxazolidinones inhibit protein synthesis by binding at the P site at the ribosomal 50S subunit. Resistance to other protein synthesis inhibitors does not affect oxazolidinone activity, however rare development of oxazolidinone resistance cases, associated with 23S rRNA alterations during treatment have been reported. Linezolid inhibits bacterial protein synthesis through a mechanism of action different from that of other antibacterial agents; therefore, cross-resistance between linezolid and other classes of antibiotics is unlikely.

LEVOMYSOL Absorption

Linezolid is rapidly and extensively absorbed after oral dosing. Maximum plasma concentrations are reached approximately 1 to 2 hours after dosing, and the absolute bioavailability is approximately 100%.

LEVOMYSOL side effects and Toxicity

Clinical signs of acute toxicity lead to decreased activity, ataxia, vomiting and tremors.

LEVOMYSOL Patient Information

LEVOMYSOL Organisms Affected

Gram negative and gram positive bacteria